A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.The AAPS journal · 2011
   Trial
2. Modeling the influence of growth hormone on lipolysis.Journal of pharmacokinetics and pharmacodynamics · 2002
   Trial
3. Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.British journal of clinical pharmacology · 2001
   Trial
4. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.British journal of clinical pharmacology · 1998
   Trial
5. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2014
   Article
6. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.British journal of clinical pharmacology · 2008
   Article
7. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.Journal of pharmacokinetics and pharmacodynamics · 2007
   Article
8. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.Journal of pharmacokinetics and pharmacodynamics · 2006
   Review
9. Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.Journal of pharmacokinetics and pharmacodynamics · 2005
   Article
10. Volterra series in pharmacokinetics and pharmacodynamics.Journal of pharmacokinetics and pharmacodynamics · 2003
    Article
11. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.Journal of pharmacokinetics and biopharmaceutics · 1999
    Article
12. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.Pharmaceutical research · 1999
    Article
13. Expanding clinical applications of population pharmacodynamic modelling.British journal of clinical pharmacology · 1998
    Review
14. Characterization of the dose-dependent time of peak effect in indirect response models.Journal of pharmacokinetics and biopharmaceutics · 1998
    Article
15. Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes.Journal of pharmacokinetics and biopharmaceutics · 1997
    Article
16. Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.Pharmaceutical research · 1997
    Article
17. Convergence of direct and indirect pharmacodynamic response models.Journal of pharmacokinetics and biopharmaceutics · 1995
    Article
18. Brain microdialysis and PK/PD correlation of pregabalin in rats.European journal of drug metabolism and pharmacokinetics
    Article

Corrections and comments

• Commented on by
  Convergence of direct and indirect pharmacodynamic response models.1995

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as